Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 61, Issue 1, 2006, Pages 72-78

  Bousquet, J ^a   Aubier, M ^b   Sastre, J ^c   Izquierdo, J L ^d   Adler, L M ^e   Hofbauer, P ^f   Rost, K D ^f   Harnest, U ^f   Kroemer, B ^f   Albrecht, A ^g   Bredenbroker D ^g  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b BICHAT HOSPITAL   (France)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^e Belmont Health Centre   (United Kingdom)

^f ALTANA Pharma AG ^*

^g ALTANA PHARMA AG   (Germany)

Author keywords

Asthma; Beclomethasone; ICS; PDE4 inhibitor; Roflumilast

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; PLACEBO; ROFLUMILAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 33644904643     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2005.00931.x     Document Type: Article

References (32)

1. Brogger J Bakke P Eide GE Johansen B Andersen A Gulsvik A Long-term changes in adult asthma prevalence Eur Respir J 2003 21 468 472
2. Adams NP Bestall JB Jones PW Inhaled beclomethasone versus placebo for chronic asthma Cochrane Database Syst Rev 2000 1 q3 CD002738
3. Adams N Bestall J Jones P Inhaled beclomethasone at different doses for long-term asthma Cochrane Database Syst Rev 2001 1 CD002879
4. Jones C Santanello NC Boccuzzi SJ Wogen J Strub P Nelsen LM Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data J Asthma 2003 40 93 101
5. Leblanc P Mink S Keistinen T Saarelainen PA Ringdal N Payne SL A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma Allergy 1994 49 380 385
6. Davies RJ Stampone P O'Connor BJ Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose Respir Med 1998 92 Suppl. A 23 31
7. Beavo JA Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms Physiol Rev 1995 75 725 748
8. Conti M Jin SL The molecular biology of cyclic nucleotide phosphodiesterases Prog Nucleic Acid Res Mol Biol 1999 63 1 38
9. Francis SH Turko IV Corbin JD Cyclic nucleotide phosphodiesterases: relating structure and function Prog Nucleic Acid Res Mol Biol 2001 65 1 52
10. Lipworth BJ Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease Lancet 2005 365 167 175
11. Torphy TJ Phosphodiesterase isozymes: molecular targets for novel antiasthma agents Am J Respir Crit Care Med 1998 157 351 370
12. Torphy TJ Undem BJ Phosphodiesterase inhibitors: new opportunities for the treatment of asthma Thorax 1991 46 512 523
13. Moore AR Willoughby DA The role of cAMP regulation in controlling inflammation Clin Exp Immunol 1995 101 387 389
14. Bundschuh DS Eltze M Barsig J Wollin L Hatzelmann A Beume R In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor J Pharmacol Exp Ther 2001 297 280 290
15. Hatzelmann A Schudt C Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro J Pharmacol Exp Ther 2001 297 267 279
16. Zech K David M Seiberling M Weimar C Bethke T Wurst W High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor Eur Respir J 2001 18 Suppl. 33 20s
17. National Institutes of Health; National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NIH Publication 97-4051 July 1997
18. Standardization of spirometry, 1994 update American Thoracic Society Am J Respir Crit Care Med 1995 152 1107 1136
19. Quanjer PH Tammeling GJ Cotes JE Pedersen OF Peslin R Yernault JC Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society Eur Respir J Suppl 1993 16 5 40
20. Keatings VM Jatakanon A Worsdell YM Barnes PJ Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD Am J Respir Crit Care Med 1997 155 542 548
21. Martin RJ Therapeutic significance of distal airway inflammation in asthma J Allergy Clin Immunol 2002 109 Suppl. 2 S447 S460
22. Adcock IM Lane SJ Corticosteroid-insensitive asthma: molecular mechanisms J Endocrinol 2003 178 347 355
23. Spector S Noncompliance with asthma therapy - are there solutions J Asthma 2000 37 381 388
24. Global Initiative for Asthma Global Strategy for Asthma Management and Prevention NIH Publication 02-3656. Updated 2004 from the 2003 document. Available at: (accessed March 7, 2005)
25. Kanniess F Richter K Bohme S Jorres RA Magnussen H Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Eur Respir J 2002 20 853 858
26. O'Sullivan S Akveld M Burke CM Poulter LW Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation Am J Respir Crit Care Med 2003 167 745 750
27. Malmstrom K Rodriguez-Gomez G Guerra J Villaran C Pineiro A Wei LX et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial Ann Intern Med 1999 130 487 495
28. Kumar RK Herbert C Thomas PS Wollin L Beume R Yang M et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma J Pharmacol Exp Ther 2003 307 349 355
29. Gross G Thompson PJ Chervinsky P Vanden Burgt J Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma Chest 1999 115 343 351
30. Boulet LP Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients Chest 1998 113 587 592
31. Cochrane MG Bala MV Downs KE Mauskopf J Ben-Joseph RH Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique Chest 2000 117 542 550
32. Giraud V Roche N Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability Eur Respir J 2002 19 246 251